Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...